US Patent

US10464905 — Compounds useful as kinase inhibitors

Method of Use · Assigned to Loxo Oncology Inc · Expires 2036-12-16 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel compounds that inhibit Bruton's tyrosine kinase (BTK) and are useful for treating conditions such as cancer, lymphoma, leukemia, and immunological diseases.

USPTO Abstract

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3518 —
U-3518 —

Patent Metadata

Patent number
US10464905
Jurisdiction
US
Classification
Method of Use
Expires
2036-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Loxo Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.